THE RESULTS OF TREATMENT USING SACUBITRIL/VALSARTAN IN HEART FAILURE PATIENTS WITH REDUCED LEFT VENTRICULAR EJECTION AT THAI NGUYEN NATIONAL HOSPITAL
Main Article Content
Abstract
Objective: To describe the treatment results of patients with heart failure with reduced ejection fraction using a regimen using Saubitril/valartan. Method: A descriptive, prospective, longitudinal study of 58 patients with heart failure with reduced ejection fraction. Results: There were more men than women with a male/female ratio of 2.41. The mean age was 64.69 ± 13.2 years, most of whom were 65 years or older. The improvement in NYHA classification was statistically significant with p < 0.05. The improvement in left ventricular ejection fraction, left ventricular end-systolic and end-diastolic dimensions was statistically significant with p < 0.05. The change in NT-proBNP concentration (median 1937 pg/ml vs 911 pg/ml) was statistically significant with p = 0,00 < 0.05. 56.9% of patients participating in the study achieved treatment effectiveness in improving NYHA classification, improving EF and improving NT-proBNP concentration. Conclusion: The heart failure treatment regimen using Sacubitril/valsartan is effective in treating heart failure with reduced ejection fraction, improving all 3 indexes including ejection fraction, reducing NT-proBNP concentration and improving NYHA classification.
Keywords
Suy tim phân suất tống máu giảm, ARNI, kết quả điều trị suy tim.
Article Details
References
2. Ran, J. et al. Global, regional, and national burden of heart failure and its underlying causes, 1990–2021: results from the global burden of disease study 2021. Biomarker Research 13, 16, doi:10.1186/s40364-025-00728-8 (2025).
3. McMurray, J. J. V. et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. 371, 993-1004, doi:doi:10.1056/ NEJMoa1409077 (2014).
4. Packer, M. et al. Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure. Circulation 131, 54-61, doi:10.1161/CIRCULATIONAHA.114.013748 (2015).
5. Wilcox, J. E., Fang, J. C., Margulies, K. B. & Mann, D. L. Heart Failure With Recovered Left Ventricular Ejection Fraction. 76, 719-734, doi:doi:10.1016/j.jacc.2020.05.075 (2020).
6. Armstrong, P. W. et al. Sequential Evaluation of NT-proBNP in Heart Failure. 10, 677-688, doi:doi:10.1016/j.jchf.2022.04.015 (2022).
7. Nguyễn, K. N. & Nguyễn, T. D. Nghiên cứu đặc điểm lâm sàng, cận lâm sàng, và đánh giá kết quả điều trị suy tim phân suất tống máu giảm bằng thuốc Sacubitril/Valsartan. Tạp chí Y Dược học Cần Thơ, 29-35, doi:10.58490/ ctump.2023i61.1232 (2023).
8. Đông, N. T. & Hảo, T. T. T. Nghiên cứu hiệu quả và tính an toàn theo liều của thuốc arni (sacubitril/valsartan) ở bệnh nhân suy tim mạn có phân suất tống máu thất trái giảm. Tạp chí Y học lâm sàng Bệnh viện Trung Ương Huế, doi:10.38103/jcmhch.89.14 (2023).
9. Kim, H.-M., Kim, K.-H., Park, J.-S. & Oh, B.-H. Beneficial Effect of Left Ventricular Remodeling after Early Change of Sacubitril/Valsartan in Patients with Nonischemic Dilated Cardiomyopathy. 57, 416 (2021).
10. Mann, D. L. et al. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA cardiology 7, 17-25, doi:10.1001/jamacardio.2021.4567 (2022).